S
Scott M. Grundy
Researcher at University of Texas Southwestern Medical Center
Publications - 849
Citations - 246629
Scott M. Grundy is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Cholesterol & Lipoprotein. The author has an hindex of 187, co-authored 841 publications receiving 231821 citations. Previous affiliations of Scott M. Grundy include University of California, San Francisco & University of California, Davis.
Papers
More filters
Journal ArticleDOI
Cholesterol and coronary heart disease: The 21st century
TL;DR: Although much can be achieved through application of current knowledge in prevention efforts, further advances through new research will be required to remove coronary heart disease as a major cause of death in the United States.
Journal ArticleDOI
Metabolic effects of dietary stearic acid in mice: changes in the fatty acid composition of triglycerides and phospholipids in various tissues.
TL;DR: The fatty acid patterns of triglycerides and phospholipids extracted from adipose tissue, liver, heart, kidney, spleen, and lung of 3 groups of C57BL/6 mice were determined after feeding diets rich in palmitic acid and oleic acid for 9 months.
Journal ArticleDOI
National cholesterol education program recommendations for cholesterol testing in young adults: A science-based approach
James I. Cleeman,Scott M. Grundy +1 more
TL;DR: The NCEP recommendations regarding cholesterol testing in young adults and the scientific rationale for the recommendations are outlined.
Journal ArticleDOI
Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease.
Gloria Lena Vega,Scott M. Grundy +1 more
TL;DR: LLB may not prove to be a better indicator of coronary risk in normolipidemic people, but LDL-apoB could be a superior predictor of risk in HTG patients.
Journal ArticleDOI
Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations: Comparison of gemfibrozil vs lovastatin therapy
Gloria Lena Vega,Scott M. Grundy +1 more
TL;DR: Lovastatin seems to have certain advantages over gemfibrozil for treatment of elevated plasma triglyceride levels accompanied by borderline high total cholesterol and raised apolipoprotein B levels; therefore, lovastatin therapy should be considered as one approach for management of this condition.